OCUL Ocular Therapeutix Inc

NASDAQ
$7.29

Ocular Therapeutix Inc (OCUL) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.0% since its last earnings release on August 3, 2026.

Ocular Therapeutix Beat Consensus Estimates
Monday, August 3, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.36)
Rev est $13.91M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $9.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ocular Therapeutix Inc

Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

Sector

Healthcare

Industry

Drug Delivery

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.